Real Time Search
CES A80 :
CES 120 :
Total Turn.

China Information Technology Development Limited (CITD) and Moneda Pte Ltd Join Forces in Revolutionary Partnership To Serve The US$43billion Global Algorithmic Trading Market

2023-10-03 08:03:00

HONG KONG, Oct. 3, 2023 /PRNewswire/ -- China Information Technology Development Limited (CITD) (HKEX: 8178), a leading technology company specializing in AI and cloud technologies, is excited to announce a strategic partnership with Moneda Pte Ltd, a Singapore-based entity renowned for its expertise in developing and licensing investment risk management algorithms. The collaboration, formalized through a Memorandum of Understanding (MOU), is poised to drive innovation and advancements in investment solutions with the objective of serving the global algorithmic trading market.  Based on market research, the global algorithmic trading market is expected to reach USD$43billion by 2030 – representing a 12.2% CAGR from 2022 to 2030[1].

Moneda's exceptional proficiency in investment risk management algorithms aligns seamlessly with CITD's vision to integrate advanced AI and blockchain technologies into traditional businesses. Recognizing the potential of Moneda's products in the tokenization of Real World Assets (RWA), this partnership is a testament to CITD's commitment to revolutionize the investment landscape.

CITD, as a technology powerhouse, specializes in the integration of cutting-edge solutions such as Artificial Intelligence (AI), Blockchain Technologies, Digital Ownership Tokens (DOTs) Technologies, and Web 3+2 As a Service (W5AAS), collectively referred to as "Web 5 Solutions". The collaboration will see both parties pooling their expertise and resources to create innovative products.

Key Highlights of the Partnership:

1. Joint Development: CITD and Moneda will collaborate on the development of investment risk management algorithms and the native tokenization of RWA. This joint effort will drive the creation of groundbreaking investment products.

2. Resource Allocation: Both parties are committed to allocating the necessary resources, including manpower, technology, and capital, to ensure the successful execution of the project.

3. Intellectual Property: All intellectual property developed during the collaboration will be owned jointly and severally by both parties, unless otherwise stipulated in writing.

4. Integration of AI and Algorithmic Trading: The partnership will focus on integrating Artificial Intelligence (AI) and Algorithmic Trading to enhance and implement an innovative trading system. This endeavor encompasses research and development, data analysis and processing, system integration and deployment, risk management and compliance, and monitoring and evaluation.

Daniel Wong, CEO of CITD, expressed enthusiasm about the partnership, stating, "CITD is dedicated to pushing the boundaries of innovation in investment solutions. Our collaboration with Moneda represents a significant step towards harnessing advanced technologies to create new, value-driven investment opportunities. Together, we aim to redefine the investment landscape."

Mr. Charles Villeneuve of Moneda Pte Ltd, shared his optimism, saying, "We are excited to embark on this journey with CITD, a company renowned for its technological prowess. This partnership not only complements our strengths but also signifies a dynamic shift in the investment industry. We look forward to co-creating groundbreaking solutions."

The CITD and Moneda partnership marks a milestone in the journey towards innovative investment solutions that are underpinned by cutting-edge technologies.


For more information about CITD, please visit
For more information about Moneda, please visit 

For media inquiries, please contact:

China Information Technology Development Limited


PR Newswire News

Brinc Introduces New Partners & Collaborators for 2024 Web3 & Gaming Programs
Inaugural Asia FII PRIORITY Summit Powered By FII Institute To Take Place In Hong Kong On 7 & 8 December
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
N mobile Makes Its Disruptive Debut - Probably the best value travel & lifestyle mobile brand in Hong Kong
Kai Tin Shopping Centre Unveils Its New Wing with an Exciting New Look and New Shops
The Grand Opening of River Cam Dermatology Centre and River Cam Nutrition Center (Shatin) Amalgamates Ancient Chinese Medicine Skin Care Wisdom and Nutrition Science
First Digital's Stablecoin FDUSD Hits US$1 Billion Market Cap on Strong Market Adoption
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
The 2023 Investor Open Day of Zylox-Tonbridge was successfully held
inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
MINISO Group Responded to Unusual Price and Trading Volume Movements and Increase Plan in Shareholding by Managements
Sun Hung Kai Properties' flagship project TOWNPLACE WEST KOWLOON unveils 53,000-sq. ft. TP SOCIAL CLUB, showcasing the "Bleisure Lifestyle"
Reimagining education: 2023 Yidan Prize Summit explores innovative ideas that spark change
SUNeVision Partners with Digital Edge to Fast-track Customers' Regional Expansion
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
Govee Partners with Warner Bros. for "Aquaman and the Lost Kingdom" to Bring an Immersive Lighting Experience to Fans
Back to Top